WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "47a7f1b1-8f93-479a-a524-6222381512ae"}, "_deposit": {"created_by": 3, "id": "14133", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "14133"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00014133", "sets": ["1134"]}, "author_link": ["362", "20454", "24146", "329", "24147", "21459", "361", "24145", "24144", "97"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-08-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "1419", "bibliographicPageStart": "1413", "bibliographicVolumeNumber": "140", "bibliographic_titles": [{"bibliographic_title": "Journal of Cancer Research and Clinical Oncology"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose Prostate-specific antigen (PSA) is a useful biomarker of prostate cancer (PCa). High-risk localized PCa is defined using T stage, Gleason score (GS), and PSA. However, PSA level defining high-risk PCa is at most 20 ng/mL. In PCa patients with high PSA, it is unclear whether PSA itself can be a prognostic factor. Methods Of 642 patients who were diagnosed as PCa, 90 patients with PSA \u003e 100 ng/mL were retrospectively analyzed. Patients were divided into three groups according to PSA level: very high (\u003e1,000 ng/mL), moderately high (200-1,000 ng/mL), and slightly high (100-200 ng/mL). Results There were no significant differences in overall survival or PCa-specific survival (PCaSS) among the three groups. Regardless of PSA level, high M stage and GS significantly reduced PCaSS. When the risk classification was made using M stage and GS (high risk = M1 and GS ≥ 9, low risk = M0 and GS \u003c 9, and intermediate risk = others), PCaSS was significantly different among high-, intermediate-, and low-risk groups with 5-year survival rates of 58.2, 80.6, and 100 %, respectively. Although there were no differences in treatment performed during the castration-resistant stage, patients undergoing alternative anti-androgen and zoledronic acid treatment had better PCaSS after being castration-resistant. Conclusions As PSA could not be a prognostic factor in PCa patients with high PSA \u003e 100 ng/mL, the novel risk classification using M stage and GS may help clinicians to predict PCaSS and to plan follow-up schedules after diagnosis. © 2014 Springer-Verlag Berlin Heidelberg.", "subitem_description_type": "Abstract"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer-Verlag"}]}, "item_4_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s00432-014-1681-8", "subitem_relation_type_select": "DOI"}}]}, "item_4_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA0025708X", "subitem_source_identifier_type": "NCID"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0171-5216", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Izumi, Kouji"}], "nameIdentifiers": [{"nameIdentifier": "362", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80646787", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=80646787"}, {"nameIdentifier": "80646787", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000080646787"}]}, {"creatorNames": [{"creatorName": "Lin, Wen-Jye"}], "nameIdentifiers": [{"nameIdentifier": "24144", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyamoto, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "24145", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Huang, Chiung-Kuei"}], "nameIdentifiers": [{"nameIdentifier": "24146", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maolake, Aerken"}], "nameIdentifiers": [{"nameIdentifier": "24147", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kitagawa, Yasuhide"}], "nameIdentifiers": [{"nameIdentifier": "361", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "00452102", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000000452102"}]}, {"creatorNames": [{"creatorName": "Kadono, Yoshifumi"}], "nameIdentifiers": [{"nameIdentifier": "329", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10397218", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=10397218"}, {"nameIdentifier": "10397218", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000010397218"}]}, {"creatorNames": [{"creatorName": "Konaka, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "21459", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40334768", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40334768"}, {"nameIdentifier": "40334768", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000040334768"}]}, {"creatorNames": [{"creatorName": "Mizokami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "97", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50248580"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=50248580"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000050248580"}]}, {"creatorNames": [{"creatorName": "Namiki, Mikio"}], "nameIdentifiers": [{"nameIdentifier": "20454", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "70155985", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=70155985"}, {"nameIdentifier": "70155985", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000070155985"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-03"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ME-PR-IZUMI-K-1413.pdf", "filesize": [{"value": "521.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 521799.99999999994, "url": {"label": "ME-PR-IZUMI-K-1413.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/14133/files/ME-PR-IZUMI-K-1413.pdf"}, "version_id": "91471d34-052c-43fd-b116-4d81d52545e4"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Castration-resistant prostate cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Gleason score", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Prostate cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Prostate-specific antigen", "subitem_subject_scheme": "Other"}, {"subitem_subject": "TNM classification", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level"}]}, "item_type_id": "4", "owner": "3", "path": ["1134"], "permalink_uri": "http://hdl.handle.net/2297/39037", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-03"}, "publish_date": "2017-10-03", "publish_status": "0", "recid": "14133", "relation": {}, "relation_version_is_last": true, "title": ["Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level"], "weko_shared_id": -1}
Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level
http://hdl.handle.net/2297/39037
http://hdl.handle.net/2297/390373d3367f4-6e4b-46ad-af98-0ad04ddd25a2
名前 / ファイル | ライセンス | アクション |
---|---|---|
ME-PR-IZUMI-K-1413.pdf (521.8 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-03 | |||||
タイトル | ||||||
タイトル | Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Izumi, Kouji
× Izumi, Kouji× Lin, Wen-Jye× Miyamoto, Hiroshi× Huang, Chiung-Kuei× Maolake, Aerken× Kitagawa, Yasuhide× Kadono, Yoshifumi× Konaka, Hiroyuki× Mizokami, Atsushi× Namiki, Mikio |
|||||
書誌情報 |
Journal of Cancer Research and Clinical Oncology 巻 140, 号 8, p. 1413-1419, 発行日 2014-08-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0171-5216 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA0025708X | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s00432-014-1681-8 | |||||
出版者 | ||||||
出版者 | Springer-Verlag | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose Prostate-specific antigen (PSA) is a useful biomarker of prostate cancer (PCa). High-risk localized PCa is defined using T stage, Gleason score (GS), and PSA. However, PSA level defining high-risk PCa is at most 20 ng/mL. In PCa patients with high PSA, it is unclear whether PSA itself can be a prognostic factor. Methods Of 642 patients who were diagnosed as PCa, 90 patients with PSA > 100 ng/mL were retrospectively analyzed. Patients were divided into three groups according to PSA level: very high (>1,000 ng/mL), moderately high (200-1,000 ng/mL), and slightly high (100-200 ng/mL). Results There were no significant differences in overall survival or PCa-specific survival (PCaSS) among the three groups. Regardless of PSA level, high M stage and GS significantly reduced PCaSS. When the risk classification was made using M stage and GS (high risk = M1 and GS ≥ 9, low risk = M0 and GS < 9, and intermediate risk = others), PCaSS was significantly different among high-, intermediate-, and low-risk groups with 5-year survival rates of 58.2, 80.6, and 100 %, respectively. Although there were no differences in treatment performed during the castration-resistant stage, patients undergoing alternative anti-androgen and zoledronic acid treatment had better PCaSS after being castration-resistant. Conclusions As PSA could not be a prognostic factor in PCa patients with high PSA > 100 ng/mL, the novel risk classification using M stage and GS may help clinicians to predict PCaSS and to plan follow-up schedules after diagnosis. © 2014 Springer-Verlag Berlin Heidelberg. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa |